NIPER Hajipur, Boehringer Ingelheim India Join Hands to Fast-track Translational Pharma Research

Boehringer Ingelheim will extend access to its opnMe open science platform, which provides researchers with compounds, data, and tools to support drug discovery.

National Institute of Pharmaceutical Education and Research, Hajipur, has entered into a strategic partnership with Boehringer Ingelheim India to strengthen translational pharmaceutical research.

The partnership is expected to improve research capabilities, expand scientific access, and create pathways for early-stage discoveries to move toward clinical development.

As part of the arrangement, Boehringer Ingelheim will extend access to its opnMe open science platform, which provides researchers with compounds, data, and tools to support drug discovery.

This is expected to enable scientists at NIPER Hajipur to engage in more collaborative and innovation-driven research, while also generating proof-of-concept data that can be scaled into preclinical studies.

The initiative will also create hands-on training opportunities for students, strengthening the talent pipeline in pharmaceutical sciences.

The agreement was signed in New Delhi in the presence of senior government officials. The collaboration is also expected to position NIPER Hajipur as a key centre for translational pharmacology in India.

Highlighting the importance of such partnerships, officials reiterated that closer engagement between academia and industry is essential to bridge gaps in commercialisation and to foster innovation ecosystems capable of delivering next-generation therapies.

IPC Collaborations to Strengthen Drug Quality & Safety

In parallel developments, the Indian Pharmacopoeia Commission has signed separate agreements with the Pharmaceuticals and Medical Devices Bureau of India and NIPER Hajipur to strengthen medicine quality and patient safety.

The IPC-PMBI collaboration will focus on quality assurance of medicines distributed through Jan Aushadhi Kendras, including batch testing and promoting rational drug use through the National Formulary of India.

Efforts will also be directed toward improving pharmacovigilance by encouraging reporting of adverse drug reactions through digital tools such as QR codes and helplines.

Training and awareness programmes for pharmacists and stakeholders are planned to enhance understanding of drug safety and public health responsibilities.

Advanced Research & Pharmacopoeial Standards Development

The IPC’s partnership with NIPER Hajipur will further extend into advanced research areas, including impurity profiling, the development of analytical methods, and the establishment of quality standards for emerging therapies like biologics and gene-based treatments.

These initiatives will support the evolution of evidence-based pharmacopoeial standards in India.

Stay tuned for more such updates on Digital Health News